

# Johan Hansson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3649459/publications.pdf>

Version: 2024-02-01

48  
papers

1,779  
citations

361413

20  
h-index

289244

40  
g-index

48  
all docs

48  
docs citations

48  
times ranked

4162  
citing authors

#	ARTICLE	IF	CITATIONS
1	Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 736-740.e6.	0.7	4
2	A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma. <i>Acta Oncologica</i> , 2022, 61, 14-21.	1.8	1
3	Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families. <i>BMC Public Health</i> , 2021, 21, 692.	2.9	4
4	PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma. <i>Scientific Reports</i> , 2021, 11, 11023.	3.3	6
5	Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. , 2021, 9, e002171.		12
6	AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma. <i>Cell Death and Differentiation</i> , 2020, 27, 2081-2098.	11.2	20
7	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. <i>Cell Death and Disease</i> , 2020, 11, 882.	6.3	10
8	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. <i>Onc Immunology</i> , 2020, 9, 1792058.	4.6	30
9	Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib. <i>Melanoma Research</i> , 2020, 30, 443-454.	1.2	4
10	PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. <i>Onc Immunology</i> , 2020, 9, 1786888.	4.6	29
11	Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 51.	2.8	5
12	High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 513-522.	4.2	6
13	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	21.4	138
14	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 386-394.	1.2	17
15	Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. <i>Cell Death and Disease</i> , 2019, 10, 663.	6.3	16
16	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. <i>Frontiers in Immunology</i> , 2019, 10, 2766.	4.8	23
17	Targeting <sc>CDK</sc> 2 overcomes melanoma resistance against <sc>BRAF</sc> and Hsp90 inhibitors. <i>Molecular Systems Biology</i> , 2018, 14, e7858.	7.2	53
18	Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness. <i>Cancer Immunology Research</i> , 2018, 6, 528-538.	3.4	45

#	ARTICLE	IF	CITATIONS
19	Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. <i>PLoS ONE</i> , 2018, 13, e0206942.	2.5	35
20	Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma. <i>Cancer Research</i> , 2018, 78, 5970-5979.	0.9	236
21	Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3749-3756.	3.7	8
22	Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma. <i>International Journal of Cancer</i> , 2017, 141, 1345-1354.	5.1	8
23	Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2606-2612.	0.7	18
24	<sup>17</sup> Np73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 631-638.	4.4	14
25	Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. <i>Cell Death and Disease</i> , 2017, 8, e3029-e3029.	6.3	35
26	Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. <i>BMC Cancer</i> , 2017, 17, 584.	2.6	11
27	Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. <i>Oncotarget</i> , 2017, 8, 21539-21553.	1.8	103
28	Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe &ndash; a systematic review of the literature. <i>Clinical Epidemiology</i> , 2016, 8, 109.	3.0	91
29	Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden. <i>International Journal of Cancer</i> , 2016, 139, 543-553.	5.1	11
30	Epidemiology of cutaneous melanoma in Sweden&rsquo;Stage&rsquo;specific survival and rate of recurrence. <i>International Journal of Cancer</i> , 2016, 139, 2722-2729.	5.1	49
31	Novel rapid liquid chromatography tandem massspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state. <i>Biomedical Chromatography</i> , 2016, 30, 1234-1239.	1.7	6
32	The role of germline alterations in the DNA damage response genes <i>BRIP1</i> and <i>BRCA2</i> in melanoma susceptibility. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 601-611.	2.8	13
33	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1066-1069.	0.7	13
34	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. <i>Nature Genetics</i> , 2015, 47, 987-995.	21.4	218
35	Short-term Results of a Magnetic Resonance Imaging&quot;Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. <i>JAMA Surgery</i> , 2015, 150, 512.	4.3	83
36	BRAFV600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases. <i>JAMA Dermatology</i> , 2015, 151, 410.	4.1	27

#	ARTICLE	IF	CITATIONS
37	Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study. <i>Journal of Investigative Dermatology</i> , 2014, 134, 287-290.	0.7	18
38	Laminins 411 and 421 differentially promote tumor cell migration via $\alpha 6 \beta 1$ integrin and MCAM (CD146). <i>Matrix Biology</i> , 2014, 38, 69-83.	3.6	53
39	High risk of tobacco-related cancers in <i>CDKN2A</i> mutation-positive melanoma families. <i>Journal of Medical Genetics</i> , 2014, 51, 545-552.	3.2	73
40	Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. <i>Journal of Investigative Dermatology</i> , 2014, 134, 3000-3003.	0.7	8
41	Investigation of a putative melanoma susceptibility locus at chromosome 3q29. <i>Cancer Genetics</i> , 2014, 207, 70-74.	0.4	3
42	Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. <i>Cancer Epidemiology</i> , 2014, 38, 93-99.	1.9	20
43	An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8517-8517.	1.6	11
44	KIT, NRAS, BRAF, and PTEN alterations in acral lentiginous melanomas.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8588-8588.	1.6	1
45	Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 144-152.	10.7	93
46	Familial Cutaneous Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2010, 685, 134-145.	1.6	41
47	Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2696-2704.	0.7	34
48	Familial Melanoma. <i>Surgical Clinics of North America</i> , 2008, 88, 897-916.	1.5	22